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Abstract
To see if variations in timing of rapamycin (Rapa), administered to middle aged mice
starting at 20 months, would lead to different survival outcomes, we compared three
dosing regimens. Initiation of Rapa at 42 ppm increased survival significantly in both
male and female mice. Exposure to Rapa for a 3-month period led to significant
longevity benefit in males only. Protocols in which each month of Rapa treatment
was followed by a month without Rapa exposure were also effective in both sexes,
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though this approach was less effective than continuous exposure in female mice.
Interpretation of these results is made more complicated by unanticipated variation in
patterns of weight gain, prior to the initiation of the Rapa treatment, presumably due
to the use of drug-free food from two different suppliers. The experimental design
included tests of four other drugs, minocycline, β-guanidinopropionic acid, MitoQ,
and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), but none
of these led to a change in survival in either sex.
KEYWORDS

17‐DMAG, minocycline, MitoQ, rapamycin, survival, β‐GPA
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17-dimethylaminoethylamino-17-demethoxygeldanamycin

hy-

drochloride (17-DMAG), which inhibits HSP90 (Jez et al., 2003);
The NIA Interventions Testing Program (ITP) showed in 2009 that

Minocycline (Min), a member of a class of that includes tetracycline

male or female mice given the mTORC1 inhibitor rapamycin (Rapa)

and doxycycline (Klein & Cunha, 1995); β-GPA (β-guanadinopropi-

from age 20 months had a significant increase in median lifespan

onic acid) (β-GPA), which lowers both blood glucose and blood in-

(Harrison et al., 2009) and also increased the proportion of mice alive

sulin levels, similar to the effects of dietary restriction (Ohira et al.,

at the 90th percentile survival age. Subsequent reports documented

1994); and MitoQ, a small molecule antioxidant that accumulates in

a similar degree of lifespan extension in mice given this drug starting

mitochondria in cultured cells and in vivo (Kelso et al., 2001; Smith

from 9 months of age (Miller et al., 2011) and that the degree of

et al., 2003; Smith & Murphy, 2010). None of these four agents led

extension was dependent on Rapa dose over the range of 4.7–42

to a significant increase in lifespan.

parts per million (ppm) in food (Miller et al., 2014). The combination
of Rapa with metformin led to as much as a 26% increase in female
median lifespan and 23% increase in median male lifespan (Strong

2
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et al., 2016), although these survival results were not significantly
higher than those noted in earlier experiments using the same dose

Genetically heterogeneous male and female mice, from the four-way

(14.7 ppm) of Rapa by itself. Mice treated with Rapa (14.7 ppm) from

UM-HET3 cross, were given food containing Rapa at 42 ppm from

9 months and then euthanized at 22 months showed lower incidence

20 months of age at each of the three test sites. One group of cages

of pathological changes in heart, tendon, adrenal, endometrium, and

(“Rapa 20”) received this dose for the rest of their lives. A second

liver (Wilkinson et al., 2012), among other organs, suggesting that

group (“Rapa cycles”) received Rapa for 1-month period interrupted

many aspects of aging were delayed or decelerated by Rapa, and

by 1 month periods without drug. The third group (“Rapa 20–23”)

that this retardation of age-related changes was responsible for

received Rapa for the 3-month period starting at age 20 months,

postponement of lethal illnesses and lifespan extension. Studies

but not thereafter. Kaplan–Meier plots are shown in Figure 1, and

with higher doses of rapamycin, delivered either orally or intraper-

summary statistics, pooled across sites, are collected in Table 1. In

itoneally, also had beneficial effects on lifespan extension and on

male mice, all three dosage schedules led to a similar increase in me-

cancer incidence (Bitto et al., 2016).

dian lifespan (9%–11%), and all three produced a significant result

Because it is possible that Rapa could create a mixture of bene-

by the log-rank test. The Wang–Allison (WA) test, which we use as

ficial and harmful effects, we considered the possibility that varia-

an index of extreme longevity, was significant for Rapa 20 and Rapa

tions of dose timing might lead to further increases in lifespan when

cycles, but not (p = 0.08) for the Rapa 20–23 protocol. Formal com-

compared to continuous Rapa administration. We report here lon-

parisons, using the log-rank test, between each pair of treatment

gevity results using three dosing schemes: “Rapa 20 mon” in which

protocols found no significant difference among them for male mice

Rapa is given at 42 ppm from 20 months until death; “Rapa cycles”

(0.28 < p < 0.61).

in which Rapa is given for 1-month interval interspersed with drug-

In contrast, each of the three protocols produced a distinctly dif-

free months from 20 months until death; and “Rapa 20–23,” in which

ferent level of benefit in female mice. Rapa 20 led to a 15% increase

Rapa is started at 20 months but then terminated at 23 months.

in median (p < 0.0001 by log-rank test), while Rapa cycles led to an

The ITP reports the outcome of each longevity experi-

8% increase (p < 0.0001) and Rapa 20–23 led to a mere 4% increase

ment even when the agent tested did not lead to a convinc-

in median survival (p = 0.15). The first two of these protocols also

ing longevity benefit. In 2015, the cohort used for the Rapa

led to a significant result with the WA test (p < 0.0004 in each case),

dosing study (C2015), the ITP also tested four other agents:

but Rapa 20–23 did not (p = 0.12). Pairwise comparisons among the

|
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F I G U R E 1 Kaplan–Meier survival plots for female and male mice exposed to different Rapa treatment schedules. Green circles: Rapa
given from 22 months until death. Red squares: Rapa given from 20–21, 22–23, 24–25, etc., until death. Cyan diamonds: Rapa given for
3 months only, starting at 20 months. Data are pooled from all three test sites

TA B L E 1 Survival statistics for mice treated with Rapamycin using various dosage schedules, pooled across sites

Rx

Group

Sex

Count

Median
(days)

Percent
change in
median

Controls

Pool

M

300

772

Rapa 20 mon

Pool

M

156

856

Rapa cycles

Pool

M

159

841

9

Rapa 20–23

Pool

M

153

854

11

Controls

Pool

F

280

905

Rapa 20 mon

Pool

F

136

1040

Rapa cycles

Pool

F

136

Rapa 20–23

Pool

F

136

Log-rank
p-value

90th %ile
(days)

Percent change in
90th %ile

WA
p-value

1049
11

0.0007

1148

9

0.04

0.002

1144

9

0.001

0.024

1100

5

0.08

15

<0.0001

1231

12

<0.0001

977

8

<0.0001

1203

10

0.0004

940

4

1136

4

1095

0.15

0.12

Note: p-Values derived from log-rank test, stratified by site, calculated for each sex separately. The Wang–Allison (WA) test is described in Section 4.

three dose protocols by log-rank test showed that each one differed

to 41% (rank order UT < TJL < UM), and responses to Rapa 20–23

from the other two, with p-values ranging from 0.04 to 0.0001.

varied from −11% to 13% (TJL < UM = UT).

Although our pre-specified analytical method gives first priority

Inspection of the site-specific survival plots suggests the possibil-

to evaluation of the pooled data sets, we also evaluate site-specific

ity of unanticipated artifacts with effects on lifespan because survival

results, even though each site has only one third of the mice in the

curves at several sites appear to show differences between Control

pooled set, and therefore far lower statistical power. Survival plots

and treatment cohorts prior to the initiation of Rapa administration

for each combination of sex, site, and Rapa protocol are shown in

at age 20 months (604 days). At UM, for example, each of the three

Figure S1, and site-specific statistics are collected in Table S1. These

groups of male mice, randomly assigned at weaning to one of the Rapa

revealed a striking degree of site-specific variation. For female mice,

treatment protocols, had fewer deaths than the Control mice prior to

each site showed the same pattern, that is, significant effects of the

the onset of Rapa treatment at 604 days. Similar phenomena are vis-

Rapa 20 and Rapa cycles protocol, and the absence of significant

ible in Figure S1 for TJL females and UT males. We suspect this may

benefit using the Rapa 20–23 protocol, but the extent of change in

reflect unanticipated differences between the chow provided to these

median varied a great deal, with the UM females typically showing

mice prior to 604 days; although both the Control cages and those

the smallest percentage increase in median lifespan. All three sites

destined for Rapa treatment received food with the same formula

showed a similar degree of increase in the 90th percentile age for

(Purina 5LG6), mice in the Control group received chow prepared, by

the Rapa 20 and Rapa cycles treatment group. In males, however, re-

TestDiets, using the equipment employed for production of all ITP

sponses to Rapa 20 varied from 0% to 16% increase in median (rank

drug/food mixtures, while mice in the Rapa group received 5LG6 from

order TJL < UM < UT), responses to Rapa cycles varied from −5%

a different supplier prior to 604 days of age.

4 of 10
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F I G U R E 2 Weight at 6–24 months of age for Control and Rapa-treated mice, pooled across sites. Each symbol represents the mean of
295 male and 298 female control mice at 6 months, falling to 125 males and 210 females at 24 months. Corresponding values for each Rapa
group are an average of 150 males and 135 females at 6 months, falling to an average of 81 males and 102 females at 24 months. SEM values
ranged from 0.3 to 0.8 g. All groups of Rapa males differed from Controls at p < 0.014 at ages 12, 18, and 24 months (Tukey's post hoc test
after ANOVA, stratified by site.) All Rapa females differed from Controls at p < 0.001 at 24 months only. The “Rapa 20–23” group of females
also differed from Controls (p = 0.03) at 12 months

F I G U R E 3 Kaplan–Meier survival plots for female and male mice treated with 17-DMAG, Min, bGPA, or MitoQ

Mice in the longevity cohorts were weighed at 6, 12, 18, and

at 20 months of age, consistent with the idea that unanticipated

24 months, and the mean levels for Control and the Rapa groups,

differences between the two sources of drug-free 5LG6 mouse

averaged across sites, are shown in Figure 2. Control females

chow might have contributed to the divergence of survival curves

gained weight until 18 months, but lost weight between 18 and

prior to 20 months of age.

24 months, in this cohort as in previous ITP cohorts. Each of

The cohort initiated in 2015 also included groups of mice given

the three Rapa protocols accelerated the weight loss between

17-DMAG (30 ppm, from 6 months), Min (300 ppm, from 6 months),

Control and Rapa females after 18 months. Females in all three

β-GPA (3300 ppm, from 6 months), or MitoQ (100 ppm, from

Rapa groups were significantly lighter (p < 0.001) than Controls at

7 months). The survival curves are shown in Figure 3, and statistics

24 months, but there were no significant differences in weight at

for these agents are collected in Table 2. None of the drugs led to a

18 months. In contrast, males in each of the Rapa-assigned groups

significant change in lifespan as indicated by the log-rank test, and

were lighter than Control males at 12 and at 18 months of age

none improved the proportion of mice surviving to the 90th percen-

(p < 0.005 in each case), that is, prior to their first exposure to Rapa

tile age as tested by the WA test. Corresponding statistics for each

|
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TA B L E 2 Survival statistics for mice treated with 17-DMAG, Min, bGPA or MitoQ, pooled across sites.
Median
(days)

Percent
change in
median

Log-rank
p-value

90th %ile
(days)

9

0.12

1090

4

0.13

807

5

0.99

1026

−2

0.50

764

−1

0.73

1054

0

0.86

156

784

2

0.91

1066

2

0.86

280

905

1074

−2

0.29

1094

0

0.99

Rx

Group

Sex

Count

Controls

Pool

M

300

772

17-DMAG

Pool

M

156

844

Min

Pool

M

156

bGPA

Pool

M

156

MitoQ

Pool

M

Controls

Pool

F

17-DMAG

Pool

F

136

866

−4

0.12

Min

Pool

F

136

878

−3

0.38

Percent change in
90th %ile

WA
p-value

1049

1095

bGPA

Pool

F

136

893

−1

0.91

1114

2

0.39

MitoQ

Pool

F

136

890

−2

0.67

1105

1

0.39

Note: p-Values derived from log-rank test, stratified by site, calculated for each sex separately. The Wang–Allison (WA) test is described in Section 4.

individual site are presented in Table S2. None of these four agents

et al., 2011). Chen et al. (2009) reported that rapamycin adminis-

produced a significant change in lifespan at any site.

tered at 4 mg/kg body weight by intraperitoneal injection to 22- to
24-month-old C57BL/6 male mice, every other day for only 6 weeks,

3
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increased longevity (death ratio of 0.8 versus 0.2 death ratio at
30 weeks after first treatment). In the present study, we compared
dosing schemes for microencapsulated rapamycin (eRapa) for their

Previous ITP papers have reported that encapsulated rapamycin

effects on survival, comparing continuous administration from

(eRapa) extends lifespan (including an index of maximal lifespan) when

20 months, 3-month exposure from 20 to 23 months, and treatment

given at 9 months of age at doses of 4.7, 14, and 42 ppm in food, with

every other month beginning at 20 months of age. Continuous treat-

similar effects when given at 14.7 ppm (equivalent to 2 mg/kg body

ment with 42-ppm eRapa starting at 20 months of age increased

weight per day) starting at 20 months (Harrison et al., 2009; Miller

median and 90th percentile lifespan in both males and females.

et al., 2011, 2014). A dose in food of 42 ppm is equivalent to a dose of

Treatment with eRapa every other month starting at 20 months of

7 mg/kg body weight per day for a 30 g mouse eating 5 g of chow per

age increased median and 90th percentile lifespan in both males and

day. Other groups (Anisimov et al., 2011; Fok et al., 2013) have also

females. Treatment with eRapa, starting at 20 months and stopped

documented lifespan extension in C57/BL6 and 129/Sv mice, over

at 23 months of age, increased median lifespan in males only but did

doses ranging from 0.7 mg/kg body weight to 8 mg/kg body weight.

not lead to a significant effect on our measure of survival to the 90th

However, negative side effects have been noted in mice treated with

percentile lifespan in either sex.

rapamycin, including cataracts, testicular degeneration (Wilkinson

In a previous paper, in which Rapa was used at 42 ppm starting at

et al., 2012), insulin resistance (Fok et al., 2013), and glucose intol-

age 9 months (Miller et al., 2014), median survival was increased by

erance (Lamming et al., 2012; Miller et al., 2014). One approach to

23% in males and 26% in females. Each value is substantially higher

reducing unwanted side effects of therapeutic agents is intermittent

than the corresponding changes seen in the current paper, (i.e., 11%

dosing, a common practice in cancer chemotherapy. Intermittent

in males and 15% in females), when the same dose of 42 ppm was

dosing has been reported to decrease rapamycin-induced glucose

initiated at 20 months of age. Although it is always hazardous to

intolerance, reduce rapamycin-induced loss of testicular weight and

compare results from studies done many years apart, that is, using

lessen the effects of rapamycin on the immune system in 9-month-

“historical” data rather than contemporaneous data sets, it may be

old male C57BL/6 mice (Arriola Apelo, Neuman, et al., 2016).

that this Rapa dose is more effective when given starting earlier in

In this study, we compared three different rapamycin dosing

adult life. This is in contrast to our evidence that the 14 ppm dose

regimens, in parallel, for their effects on longevity. Intermittent

is equally effective regardless of age (Harrison et al., 2009; Miller

treatment with rapamycin (2 mg/kg body weight per day, i.p.) ad-

et al., 2014).

ministered once every 5 days starting at 20 month of age reportedly

Bitto et al. (2016) evaluated the effects of rapamycin given for

extended lifespan in female C57BL/6 mice (Arriola Apelo, Pumper,

a 3-month period starting at 20–21 months of age, using C57BL/6

et al., 2016). Moreover, intermittent treatment of female 129/Sv

mice and a dose, in chow, of 126 ppm, that is, 3-fold higher than

mice with rapamycin 1.5 mg/kg body weight, three times a week

the dose we used in the current study. Treated mice had a median

for a period of 2 weeks, followed by 2 weeks without rapamycin,

survival of approximately 996 days, a 12.5% increase over the con-

also increased lifespan when started at 2 months of age (Anisimov

trol value of 885 days, pooled across sex. The paper did not include

6 of 10
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a formal test of maximum lifespan, but inspection of their Figure 4

ischemia-reperfusion injury (Adlam et al., 2005), Alzheimer's disease

suggests that their 3-month regime, equivalent to our Rapa 20–23

(McManus et al., 2011), Parkinson's disease (Ghosh et al., 2010), amy-

protocol, may have had more late-life benefit in male C57BL/6 mice

otrophic lateral sclerosis (Miquel et al., 2014), diabetic nephropathy

than in females. Although differences in base diet, mouse stock,

(Chacko et al., 2010), age-related arterial endothelial dysfunction

and vivarium conditions make a direct comparison to our own study

(Gioscia-Ryan et al., 2014), and age-related macular degeneration

impossible, it is of interest that the 12.5% increase survival in this

(Tarallo et al., 2012). MitoQ has also been administered to humans

3-month transient protocol is similar to that which we see in our

in three studies (Gane et al., 2010; Rossman et al., 2018; Snow et al.,

Rapa 20–23 males (11%) given the 42 ppm dose, though higher than

2010) and was able to reverse age-associated vascular dysfunction

the 4% increase seen in our female mice.

in old but healthy individuals (Rossman et al., 2018). Despite this va-

Our previous study (Miller et al., 2014) of the effects of differ-

riety of positive effects on health indices in these various disease

ent doses of Rapa on lifespan showed that the increased survival in

models, there were no effects on longevity in the present study.

response to increasing concentrations of rapamycin was associated

The concentration of MitoQ in the food was verified in four differ-

with higher blood levels of Rapa in females. We do not have a ready

ent batches of food sampled over a 3-year period (see Methods S2

explanation for the sexual dimorphism we have noted in responses

for methods of analysis). The mean ± SEM of the concentrations of

to the Rapa 20–23 dosing regime in the present study and would

MitoQ in the chow was 88.00 ± 19.95 ppm which is consistent with

need to conduct detailed pharmacodynamic analysis of Rapa fluctu-

the intended concentrations of MitoQ in the food. Hence, a lack of

ations at several intervals after initiation of these dosing strategies.

effect of MitoQ on lifespan is not due to instability of the drug in the

It is possible, in addition, that some of the Rapa effects involve alter-

food. In another study, however, the levels of MitoQ in the hearts

ation in microbial populations within the GI tract, which could show

and livers in the treated mice were below the detection limits when

variable time courses of drug-induced reconfiguration and recovery.

measured by LC-MS/MS relative to deuterated internal standards

Developing clinical strategies for optimal benefit in long-term Rapa

(Rodriguez-Cuenca et al., 2010). Hence, tissues levels in the mice in

treatment, with minimal side effects may require careful stepwise

this study were at least ~20-fold lower than the levels that showed

refinement and adjustment for sex-specific effects.

efficacy in previous mouse models of diseases. The low levels of

Four other agents were tested in the C2015 cohort, but none

MitoQ may be due to the poor bioavailability of MitoQ when mixed

of these led to any improvement in lifespan. Each of the four had a

with solid food due to its strong tendency to adsorb to hydropho-

plausible rationale for inclusion the study:

bic surfaces (Smith & Murphy, 2010). Therefore, it is not possible
hy-

to make any robust conclusions on the impact of MitoQ on lifespan

drochloride (17-DMAG) is a third generation, orally bioavailable,

17-dimethylaminoethylamino-17-demethoxygeldanamycin

from this study and further studies at doses higher than the one cho-

specific HSP90 inhibitor (Jez et al., 2003). 17-DMAG is a chemi-

sen in the present study may produce a different outcome.

cally modified version of Geldanamycin, a benzoquinone antibiotic

Minocycline belongs to a class of semi-synthetic antibiotics that

initially discovered in the organism Streptomyces hygroscopicus.

includes tetracycline, doxycycline and demeclocycline. Minocycline

17-DMAG effectively inhibits HSP90, has diverse anti-tumor ac-

has been found to extend lifespan in worms and Drosophila

tions (Ikebe et al., 2013), and suppresses neurotoxicity in lower or-

(Oxenkrug et al., 2012; Ye et al., 2014) and to have beneficial effects

ganisms such as D. melanogaster (Zhang et al., 2014). In addition, it

in a wide range of rodent models of human diseases. Minocycline

has a neuro-protective role in mice (Silva-Fernandes et al., 2014),

leads to improved outcomes in a mouse model of atherosclerosis

improves survival of animals exposed to near-lethal doses of radi-

(Shahzad et al., 2011), the transgenic APP/presenilin mouse model of

ation (Lu et al., 2013), and reduces inflammation (Madrigal-Matute

Alzheimer's disease (Biscaro et al., 2012), the MPTP mouse model of

et al., 2010, 2012). This spectrum of results suggested the idea that

Parkinson disease (Du et al., 2001) and after whole-body γ-irradiation

lifelong exposure to 17-DMAG might increase mouse longevity, but

in mice (Mehrotra et al., 2013) to name a few. Minocycline has also

our data give no support for this hypothesis. The concentrations of

been reported to have benefits in human trials. It was reported to im-

17-DMAG in the food were verified in six different batches of food

prove refractory rheumatoid arthritis, to improve recovery in patients

sampled over a 3 to 4-year period (see Methods S1 for methods of

with acute stroke, to improve symptoms of fragile X syndrome, and to

analysis). The mean ± SEM of the concentrations of 17-DMAG in the

improve negative symptoms in early schizophrenia (Chaudhry et al.,

chow was 30.00 ± 2.18, which matches the intended concentration.

2012; Lampl et al., 2007; Langevitz et al., 1992; Miyaoka et al., 2012;

Thus, differences in concentration in the chow do not explain the

O'Dell et al., 1997; Paribello et al., 2010; Smith et al., 2011). However,

current findings. It is possible that a different dose of 17-DMAG may

300 ppm minocycline did not modify lifespan in UM-HET3 mice. The

have a positive effect on longevity.

concentration of minocycline in the food was verified in 6 different

MitoQ is a small molecule antioxidant that accumulates in mito-

batches of food sampled over a four-year period (see Methods S3 for

chondria in cultured cells and in vivo (Kelso et al., 2001; Smith et al.,

methods of analysis). The mean (SEM) concentration of βGPA in six

2003; Smith et al., 2010). Orally administered MitoQ reportedly

batches of food pellets was 308 ± 23.2 (SEM) ppm, which was 102%

decreases pathology when applied to rodent models of age-related

of the expected concentration of 300 ppm on average. However, it

human diseases involving mitochondrial oxidative damage (Smith

is possible that concentrations higher or lower than 300 ppm may

et al., 2011; Smith et al., 2010). These include models of cardiac

produce beneficial effects on longevity.
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β-GPA is a creatine analog that stimulates AMP-activated pro-

AVID Microchip ID Systems (Catalog AVID3002); TJL used chips

tein kinase by depleting cellular energy stores (Bergeron et al.,

purchased from Locus Technology (catalog 1D-100A). A portion

2001). β-GPA treatment produces beneficial physiological effects

of the distal tail (1 cm) was taken and frozen for later analysis of

that are associated with some (but not all) longevity extending

DNA polymorphisms, after which the mouse was permitted to

treatments (Bergeron et al., 2001; Neubauer et al., 1998; Zong

awaken from the anesthesia. The duration of anesthesia was ap-

et al., 2002). For example, β-GPA treatment of mice significantly

proximately 1–2 min.

lowers both blood glucose and blood insulin levels, similar to the

Details of the methods used for health monitoring were provided

effects of dietary restriction (Ohira et al., 1994; Reznick et al.,

in Miller et al. (2014); in brief, each of the three colonies was evalu-

2007). Glucose tolerance is also improved in β-GPA treated ani-

ated four times each year for infectious agents, including pinworm.

mals, though these effects are greater in diabetic animals com-

All such tests were negative throughout the entire study period.

pared with control animals (Meglasson et al., 1993). In the present
study, β-GPA was added to food at a concentration of 3300 ppm
and fed to mice beginning at 6 months of age. The concentration

4.2 | Control and experimental diets

of β-GPA in the food was verified in six different batches of food
sampled over a 4-year period 3248 ± 116 (SEM) ppm (see Methods

Mice were originally weaned onto 5LG6 from Purina. All diets containing

S4 for methods of analysis). Despite the beneficial physiological ef-

drugs were prepared by TestDiet, Inc., a division of Purina Mills. These

fects reported in various animal models, we observed no effects of

diets were all based on the Purina 5LG6 mouse chow. Test Diets also

β-GPA on survival in the present study. This is consistent with the

provided a Control chow processed in the same way but with no added

results of a recent study in which β-GPA treatment had no effect on

drugs, which we refer to as “Test Diets control chow.” “Test Diets control

increasing survival in three different strains of C. elegans (Coleman-

chow” and mouse chow containing each of the test substances were

Hulbert et al., 2020). In that study, an effect on survival was de-

prepared at intervals of approximately 4 months. Mice in the Control

tected in only one strain, and in that strain, β-GPA reduced lifespan.

group received Test Diets Control Chow (5LG6 formulation), without
drugs added, from 6 months of age. Mice in cages destined to receive

4
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E X PE R I M E NTA L PRO C E D U R E S

4.1 | Animals

Rapa were given 5LG6 from Purina (not Test Diets Control Chow) until
Rapa was started at 20 months. Each batch of food was shipped at the
same time to each of the three test sites. 17-DMAG was obtained from
Selleckchem Chemicals LLC. It was mixed with chow at a concentration
of 30 ppm and fed to mice beginning at 6 months of age. Mito Q was a

UM-HET3 mice were produced at each of the three test sites as

gift from Mr. Greg McPherson, CEO of MitoQ Inc (Auckland, NZ). It was

previously described in detail (Harrison et al. 2014; Miller et al.,

mixed with chow at a concentration of 100 ppm and fed to mice begin-

2011; Strong et al., 2013, 2016). The mothers of the test mice were

ning at 7 months of age. Minocycline was obtained from the UM phar-

CByB6F1/J, JAX stock #100009, whose female parents are BALB/

macy. It is distributed by Actavis Pharma, Inc. It was mixed with chow at

cByJ and whose male parents are C57BL/6J. The fathers of the test

a concentration of 300 mg/kg of food (300 ppm) and fed to mice begin-

mice were C3D2F1/J, JAX stock #100004, whose mothers are C3H/

ning at 6 months of age. β-GPA was purchased from Pure Chemistry

HeJ and whose fathers are DBA/2J. For breeding cages, each site

Scientific Inc., mixed with chow at a concentration of 3300 ppm, and

used Purina 5008 mouse chow. For weanlings prior to 4 months of

fed to mice beginning at 6 months of age. Microencapsulated rapamycin

age, each site used Purina 5LG6.

was obtained from Emtora Biosciences (formerly Rapamycin Holdings)

Mice were housed as previously described (Strong et al., 2013) in
plastic cages with metal tops, using 1/4 inch corn-cob bedding (Bed

and mixed at a concentration of 42 ppm. This mixture was fed to mice
starting at 20 months of age.

O'Cobs, produced by The Andersons). Mice were given free access to
water, acidified (pH 2.5–2.7) by addition of hydrochloric acid, using
water bottles rather than an automated watering system. Mice were
housed in ventilated cages and were transferred to fresh cages every

4.3 | Removal of mice from the
longevity population

14 days. Temperature was maintained within the range of 21°C to 23°C.
At the age of 42 days, each cage was assigned to a control or

As described in detail in Miller et al. (2011), mice were removed from

test group by use of a random number table. Each mouse was then

the study because of fighting, or accidental death, typically during

briefly anesthetized by isoflurane inhalation administered either

chip implantation, or because of chip failure, or because they were

by nose cone or by an instrument designed for small animal an-

used for another experimental purpose, such as testing for blood

esthesia and a radio-frequency identification chip was implanted

levels of a test agent. If used for experimental purposes, the mice

by sterile syringe beneath the dorsal skin between the shoulder

were removed randomly from the colony. For survival analyses, all

blades, after which the wound was closed by a drop of superglue

such mice were treated as alive at the date of their removal from

(Loctite gel, purchased locally, or Nexaband S/C, purchased from

the protocol and lost to follow-up thereafter. These mice were not

Abbott Laboratories). UM and UT used chips purchased from

included in calculations of median longevity.
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4.4 | Estimation of age at death (lifespan)

STRONG et al.

inventors Zelton Dave Sharp and Randy Strong, for an encapsulated
rapamycin formulation used in this paper. Under a licensing agree-

Mice were examined twice daily for signs of ill health. Mice were

ment between Emtora Biosciences (formerly Rapamycin Holdings,

euthanized for humane reasons if so severely moribund that they

Inc.) and the University of Texas Health Science Center San Antonio,

were considered, by an experienced technician, unlikely to survive

R. Strong, and Z.D. Sharp, the University is entitled to milestone pay-

for more than an additional 48 h. A mouse was considered severely

ments and royalty on sales of microencapsulated rapamycin. The uni-

moribund if it exhibited more than one of the following clinical signs:

versity has a plan for managing conflicts of interest under its “Policy

(a) inability to eat or to drink; (b) severe lethargy, as indicated by

and Procedures for Promoting Objectivity in Research by Managing,

reluctance to move when gently prodded with a forceps; (c) severe

Reducing or Eliminating Conflicts of Interest.” Michael P. Murphy con-

balance or gait disturbance; (d) rapid weight loss over a period of

sults for Antipodean Pharmaceuticals Inc., which is developing MitoQ

1 week or more; or (e) an ulcerated or bleeding tumor. The age at

as a potential therapy and also holds patents in the use of MitoQ.

which a moribund mouse was euthanized was taken as the best
available estimate of its natural lifespan. Mice found dead were also

AU T H O R C O N T R I B U T I O N S

noted at each daily inspection.

D.E.H., R.S., and R.A.M. are the principal investigators at the three
collaborating institutions and are responsible for project design,

4.5 | Statistical methods

supervision of technical personnel, interpretation of results, and
preparation of manuscript drafts. J.F.N. and P.R. provided advice
on experimental design and interpretation, and comments on the

For each sex, we performed site-specific and combined site analy-

manuscript. E.F supervised laboratory personnel and data collection

sis. We calculated the median survival for the control group as well

at UT. M.A.J. supervised assays at the UT site. F.M. served as the

as for each treatment group. To compute the median percentage

project officer for the National Institute on Aging and contributed to

increase, we subtracted the median age in the control group from

program development, experimental design, and analysis. A.R. pro-

the corresponding value in the treatment group and divided the dif-

posed intermittent rapamycin for study; M.P.M. proposed MitoQ for

ference by median age of the control group and multiplied by 100.

study; N.M. and A.B.S. proposed β-GPA for study; M.P.M. proposed

Using a two-sided 5% significance level, we performed the log-rank

minocycline for study; S.L. suggested the 17-DMAG study.

test to determine whether survival curves for mice receiving treatment differ from the survival function for control mice. Log-rank

DATA AVA I L A B I L I T Y S TAT E M E N T

tests that pooled data across the three test sites used a method that

The data that support the findings of this study are openly available

stratifies by site. To assess the maximum lifespan, we computed

in The Jackson Laboratory Mouse Phenome Database.at https://

90th percentile age of both the treated and control mice. To deter-

phenome.jax.org/projec ts/ITP1 once the paper is published.

mine which treatments prolonged longevity in mice, we utilized the
Wang–Allison test (Wang et al., 2004). This is the Fisher exact test

ORCID

comparing the numbers of mice surviving in control and treatment

Randy Strong

group at the age corresponding to the 90th percentile of lifespan

Richard A. Miller

https://orcid.org/0000-0001-6643-3288
https://orcid.org/0000-0001-9266-9649

in the joint survival distribution. We further assessed the longevity

Peter Reifsnyder

https://orcid.org/0000-0001-5666-8040

of mice in all three sites combined using a modified version of the

David E. Harrison

https://orcid.org/0000-0003-2298-0954

Wang–Allison test in the manner with which the 2 × 2 contingency
table is constructed separately for each site. Basically, we report

REFERENCES

the sum of corresponding site-specific 2 × 2 tables cell entries as

Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A.
J., Murphy, M. P., & Sammut, I. A. (2005). Targeting an antioxidant
to mitochondria decreases cardiac ischemia-reperfusion injury. The
FASEB Journal, 19, 1088–1095.
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S.,
Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Rosenfeld, S. V.,
& Blagosklonny, M. V. (2011). Rapamyin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle,
10, 4230–4236.
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar,
H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016). Alternative
rapamycin treatment regimens mitigate the impact of rapamycin on
glucose homeostasis and the immune system. Aging Cell, 15, 28–33.
Arriola Apelo, S. I., Pumper, C. P., Baar, E. L., Cummings, N. E., &
Lamming, D. W. (2016). Intermittent administration of rapamycin extends the life span of female C57BL/6J mice. Journals of
Gerontology Series A, Biological Sciences and Medical Sciences,
71(7), 876–881.

the combined site 2 × 2 table cell entries. This allows for information from all sites to be used in a balanced manner.
AC K N OW L E D G E M E N T S
This work was funded in part by NIA grants AG022308 (DEH),
AG022303 (RAM), AG022307, and AG013319 (RS), with important facilities supported by CA034196 (DEH) and AG024824 (RAM). RS and
AR are supported by Senior Research Career Scientist Awards from the
Department of Veterans Affairs Office of Research and Development.
We wish to thank Vivian Diaz for reliable technical assistance.
C O N FL I C T O F I N T E R E S T
The University of Texas Health Science Center at San Antonio has
applied for a patent, U.S. Patent Application No. 13/128,800, by

STRONG et al.

Bergeron, R., Ren, J. M., Cadman, K. S., Moore, I. K., Perret, P., Pypaert,
M., Young, L. H., Semenkovich, C. F., & Shulman, G. I. (2001). Chronic
activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. American Journal of Physiology – Endocrinology and
Metabolism, 281, E1340–E1346.
Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012).
Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse
model for Alzheimer's disease. Neuro-Degenerative Diseases, 9,
187–198.
Bitto, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief,
E., Tung, H., Vizzini, N., Chen, B., Smith, K., Meza, D., Yajima, M.,
Beyer, R. P., Kerr, K. F., Davis, D. J., Gillespie, C. H., Snyder, J. M.,
Treuting, P. M., & Kaeberlein, M. (2016). Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.
eLife, 5, e16351.
Chacko, B. K., Reily, C., Srivastava, A., Johnson, M. S., Ye, Y., Ulasova, E.,
Agarwal, A., Zinn, K. R., Murphy, M. P., Kalyanaraman, B., & DarleyUsmar, V. (2010). Prevention of diabetic nephropathy in Ins2(+/)
(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. The
Biochemical Journal, 432, 9–19.
Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson,
P., Dursun, S., Dunn, G., & Deakin, B. (2012). Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo controlled clinical trial in patients on standard
treatment. Journal of Psychopharmacology, 26, 1185–1193.
Chen, C., Liu, Y., Liu, Y., & Pan, Z. (2009). mTOR regulation and therapeutic rejuvenation of aging hematopoietic stemcells. Science Signaling,
2, ra75.
Coleman-Hulbert, A. L., Johnson, E., Sedore, C. A., Banse, S. A., Guo, M.,
Driscoll, M., Lithgow, G. J., & Phillips, P. C. (2020). Caenorhabditis
intervention testing program: The creatine analog β-guanidinopropionic acid does not extend lifespan in nematodes. microPublication
Biology. https://doi.org/10.17912/micropub.biolog y.000207
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C.,
Chernet, E., Perry, K. W., Nelson, D. L., Luecke, S., Phebus, L. A.,
Bymaster, F. P., & Paul, S. M. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of
Parkinson's disease. Proceedings of the National Academy of Sciences
of the United States of America, 98, 14669–14674.
Fok, W. C., Zhang, Y., Salmon, A. B., Bhattacharya, A., Gunda, R., Jones,
D., Ward, W., Fisher, K., Richardson, A., & Pérez, V. I. (2013).
Short-term treatment with rapamycin and dietary restriction have
overlapping and distinctive effects in young mice. The Journals of
Gerontology Series A: Biological Sciences and Medical Sciences, 68,
108–116.
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart,
M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy,
M. P. (2010). The mitochondria-targeted anti-oxidant mitoquinone
decreases liver damage in a phase II study of hepatitis C patients.
Liver International, 30, 1019–1026.
Ghosh, A., Chandran, K., Kalivendi, S. V., Joseph, J., Antholine, W. E.,
Hillard, C. J., Kanthasamy, A., Kanthasamy, A., & Klyanaramanb,
B. (2010). Neuroprotection by a mitochondria-targeted drug in
a Parkinson's disease model. Free Radical Biology & Medicine, 49,
1674–1684.
Gioscia-Ryan, R. A., LaRocca, T. J., Sindler, A. L., Zigler, M. C., Murphy, M.
P., & Seals, D. R. (2014). Mitochondria-targeted antioxidant (MitoQ)
ameliorates age-related arterial endothelial dysfunction in mice.
Journal of Physiology, 592, 2549–2561.
Harrison, D. E., Strong, R., Allison, D. B., Ames, B. N., Astle, C. M., Atamna,
H., Fernandez, E., Flurkey, F., Javors, M. A., Nadon, N. L., Nelson, J.
F., Simpkins, J. W., Smith, D., Wilkinson, J. E., & Miller, R. A. (2014).
Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend
mouse lifespan preferentially in males. Aging Cell, 13, 273–282.

|

9 of 10

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey,
K., Nadon, N. L., Wilkinson, E., Frenkel, K., Carter, C. S., Pahor, M.,
Javors, M. A., Fernandez, E., & Miller, R. A. (2009). Rapamycin fed
late in life extends longevity of genetically heterogeneous mice.
Nature, 460, 392–396.
Ikebe, E., Kawaguchi, A., Tezuka, K., Taguchi, S., Hirose, S., Matsumoto,
T., Mitsui, T., Senba, K., Nishizono, A., Hori, M., Hasegawa, H.,
Yamada, Y., Ueno, T., Tanaka, Y., Sawa, H., Hall, W., Minami, Y.,
Jeang, K. T., Ogata, M., … Iha, H. (2013). Oral administration of an
HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into
multiple organs and improves survival period for ATL model mice.
Blood Cancer Journal, 3, e132.
Jez, J. M., Chen, J. C., Rastelli, G., Stroud, R. M., & Santi, D. V. (2003).
Crystal structure and molecular modeling of 17-DMAG in complex
with human Hsp90. Chemistry & Biology, 10, 361–368.
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K.,
Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001). Selective
targeting of a redox-active ubiquinone to mitochondria within
cells: Antioxidant and antiapoptotic properties. Journal of Biological
Chemistry, 276, 4588–4596.
Klein, N. C., & Cunha, B. A. (1995). Tetracyclines. Medical Clinics of North
America, 79, 789–801.
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M.,
Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R.
S., Guertin, D. A., Sabatini, D. M., & Baur, J. A. (2012). Rapamycininduced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science, 335, 1638–1643.
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A.,
Anca-Hershkowitz, M., & Sadeh, M. (2007). Minocycline treatment
in acute stroke: An open-label, evaluator-blinded study. Neurology,
69, 1404–1410.
Langevitz, P., Bank, I., Zemer, D., Book, M., & Pras, M. (1992). Treatment
of resistant rheumatoid arthritis with minocycline: An open study.
Journal of Rheumatology, 19, 1502–1504.
Lu, X., Nurmemet, D., Bolduc, D. L., Elliott, T. B., & Kiang, J. G. (2013).
Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: Bone marrow and small
intestine. Cell & Bioscience, 3, 36.
Madrigal-Matute, J., Fernandez-Garcia, C. E., Gomez-Guerrero, C.,
Lopez-Franco, O., Munoz-Garcia, B., Egido, J., Blanco-Colio, L. M., &
Martin-Ventura, J. L. (2012). HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis. Cardiovascular
Research, 95, 116–123.
Madrigal-Matute, J., Lopez-Franco, O., Blanco-Colio, L. M., Munoz-Garcia,
B., Ramos-Mozo, P., Ortega, L., Egido, J., & Martin-Ventura, J. L.
(2010). Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovascular Research, 86, 330–337.
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011). The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory
retention and early neuropathology in a transgenic mouse model
of Alzheimer's disease. Journal of Neuroscience, 31, 15703–15715.
Meglasson, M. D., Wilson, J. M., Yu, J. H., Robinson, D. D., Wyse, B. M.,
& de Souza, C. J. (1993). Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia
in diabetic KKAy and C57BL6Job/ob mice and increases glucose
disappearance in rhesus monkeys. Journal of Pharmacology and
Experimental Therapeutics, 266, 1454–1462.
Mehrotra, S., Pecaut, M. J., & Gridley, D. S. (2013). Effects of minocycline
on hematopoietic recovery after whole-body irradiation. In Vivo, 27,
11–28.
Miller, R. A., Harrison, D., Astle, C. M., Baur, J. A., Boyd, A. R., de Cabo,
R., Fernandez, E., Flurkey, K., Javors, M. A., Nelson, J. F., Orihuela,
C. J., Pletcher, S., Sharp, Z. D., Sinclair, D., Starnes, J. W., Wilkinson,
J. E., Nadon, N. L., & Strong, R. (2011). Rapamycin, but not resveratrol or simvastatin, extends lifespan of genetically heterogeneous

10 of 10

|

mice. Journals of Gerontology Series A, Biological Sciences and Medical
Sciences, 66, 191–201.
Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han,
M., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., Pletcher, S., Van
Roekel, S., Salmon, A. B., Sharp, Z. D., Winkleman, L., & Strong, R.
(2014). Rapamycin-mediated lifespan increase in mice is dose and
sex-dependent and is metabolically distinct from dietary restriction. Aging Cell, 13, 468–477.
Miquel, E., Cassin, A., Martínez-Palma, L., Souza, J. M., Bolattoa, C.,
Rodríguez-Botteroa, S., Logan, A., Smith, R. A. J., Murphy, M. P.,
Barbeito, L., Radi, R., & Cassina, P. (2014). Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model
of inherited amyotrophic lateral sclerosis. Free Radical Biology and
Medicine, 70, 204–213.
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K.,
Tsuchie, K., Taki, M., Ishihara, K., Araki, T., & Horiguchi, J. (2012).
Minocycline as adjunctive therapy for patients with unipolar
psychotic depression: An open-label study. Progress in NeuroPsychopharmacology and Biological Psychiatry, 37, 222–226.
Neubauer, S., Horn, M., & Schnackerz, K. (1998). Manipulating creatine
levels post-myocardial infarction—Chronic effects on left ventricular remodeling. Magnetic Resonance Materials in Physics, Biology and
Medicine, 6, 126–128.
O'Dell, J. R., Haire, C. E., Palmer, W., Drymalski, W., Wees, S., Blakely,
K., Churchill, M., Eckhoff, P. J., Weaver, A., Doud, D., Erikson, N.,
Dietz, F., Olson, R., Maloley, P., Klassen, L. W., & Moore, G. F. (1997).
Treatment of early rheumatoid arthritis with minocycline or placebo: Results of a randomized, double-blind, placebo-controlled
trial. Arthritis and Rheumatism, 40, 842–848.
Ohira, Y., Ishine, S., Tabata, I., Kurata, H., Wakatsuki, T., Sugawara, S.,
Yasui, W., Tanaka, H., & Kuroda, Y. (1994). Non-insulin and non-exercise related increase of glucose utilization in rats and mice.
Japanese Journal of Physiology, 44, 391–402.
Oxenkrug, G., Navrotskaya, V., Vorobyova, L., & Summergrad, P. (2012).
Minocycline effect on life and health span of Drosophila melanogaster. Aging and Disease, 3, 352–359.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell,
I. M., & Ethell, D. W. (2010). Open-label add-on treatment trial of
minocycline in fragile X syndrome. BMC Neurology, 10, 91.
Reznick, R. M., Zong, H., Li, J. I., Morino, K., Moore, I. K., Yu, H. J., Liu,
Z.-X., Dong, J., Mustard, K. J., Hawley, S. A., Befroy, D., Pypaert,
M., Hardie, D. G., Young, L. H., & Shulman, G. I. (2007). Agingassociated reductions in AMP-activated protein kinase activity and
mitochondrial biogenesis. Cell Metabolism, 5, 151–156.
Rodriguez-Cuenca, S., Cochemé, H. M., Logan, A., Abakumova, I., Prime,
T. A., Rose, C., Vidal-Puig, A., Smith, A. C., Rubinsztein, D. C.,
Fearnley, I. M., Jones, B. A., Pope, S., Heales, S. J. R., Lam, B. Y. H.,
Neogi, S. G., McFarlane, I., James, A. M., Smith, R. A. J., & Murphy,
M. P. (2010). Consequences of long-term oral administration of the
mitochondria-targeted antioxidant MitoQ to wild-type mice. Free
Radical Biology & Medicine, 48, 161–172.
Rossman, M. J., Santos-Parker, J. R., Steward, C. A. C., Bispham, N. Z.,
Cuevas, L. M., Rosenberg, H. L., Woodward, K. A., Chonchol, M.,
Gioscia-Ryan, R. A., Murphy, M. P., & Seals, D. R. (2018). Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension, 71, 1056–1063.
Shahzad, K., Thati, M., Wang, H., Kashif, M., Wolter, J., Ranjan, S., He, T.,
Zhou, Q., Blessing, E., Bierhaus, A., Nawroth, P. P., & Isermann, B.
(2011). Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis, 219, 74–83.
Silva-Fernandes, A., Duarte-Silva, S., Neves-Carvalho, A., Amorim, M.,
Soares-Cunha, C., Oliveira, P., Thirstrup, K., Teixeira-Castro, A., &
Maciel, P. (2014). Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph
disease. Neurotherapeutics, 11, 433–449.

STRONG et al.

Smith, R. A., Hartley, R. C., & Murphy, M. P. (2011). Mitochondriatargeted small molecule therapeutics and probes. Antioxidants &
Redox Signaling, 15, 3021–3038.
Smith, R. A., & Murphy, M. P. (2010). Animal and human studies with the
mitochondria targeted antioxidant MitoQ. Annals of the New York
Academy of Sciences, 1201, 96–103.
Smith, R. A., Porteous, C. M., Gane, A. M., & Murphy, M. P. (2003). of bioactive molecules to mitochondria in vivo. Proceedings of the National
Academy of Sciences of the United States of America, 100, 5407–5412.
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J.
D., Fung, V., Smith, R. A. J., Murphy, M. P., & Taylor, K. M. (2010).
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in
Parkinson's disease. Movement Disorders, 25, 1670–1674.
Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S.,
Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., Javors, M. A.,
de Magalhães, J. P., Marinez, P. A., McCord, J. M., Miller, B. F., Müller, M.,
Nelson, J. F., Ndukum, J., Rainger, G. E., … Harrison, D. E. (2016). Longer
lifespan in male mice treated with a weakly-estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell, 5, 872–884.
Strong, R., Miller, R. A., Astle, C. M., Baur, J. A., de Cabo, R., Fernandez,
E., Guo, W., Javors, M., Kirkland, J. L., Nelson, J. F., Sinclair, D. A.,
Teter, B., Williams, D., Zaveri, N., Nadon, N. L., & Harrison, D. E.
(2013). Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of
genetically heterogeneous mice. Journals of Gerontology Series A,
Biological Sciences and Medical Sciences, 68, 6–16.
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W.
G., Kaneko, H., Fowler, B. F., Bogdanovich, S., Albuquerque, R. J. C.,
Hauswirth, W. W., Chiodo, V. A., Kugel, J. F., Goodrich, J. A., Ponicsan,
S. L., Chaudhuri, G., Murphy, M. P., Dunaief, J. L., … Ambati, J. (2012).
DICER1 loss and Alu RNA induce age-related macular degeneration
via the NLRP3 inflammasome and MyD88. Cell, 149, 847–859.
Wang, C., Li, Q., Redden, D. T., Weindruch, R., & Allison, D. B. (2004).
Statistical methods for testing effects on “maximum lifespan”.
Mechanisms of Ageing and Development, 125, 629–632.
Wilkinson, J. E., Burmeister, L., Brooks, S. V., Carames, B., Friedline,
S., Harrison, D. E., Lotz, M., Nadon, N., Strong, R., Wood, L. K.,
Woodward, M. A., & Miller, R. A. (2012). Rapamycin Slows Aging in
Mice. Aging Cell, 11(4), 675–682.
Ye, X., Linton, J. M., Schork, N. J., Buck, L. B., & Petrascheck, M. (2014).
A pharmacological network for lifespan extension in Caenorhabditis
elegans. Aging Cell, 13, 206–215.
Zhang, Y., Casas-Tinto, S., Rincon-Limas, D. E., & Fernandez-Funez, P.
(2014). Combined pharmacological induction of hsp70 suppresses
prion protein neurotoxicity in Drosophila. PLoS One, 9, e88522.
Zong, H., Ren, J. M., Young, L. H., Pypaert, M., Mu, J., Birnbaum, M. J.,
& Shulman, G. I. (2002). AMP kinase is required for mitochondrial
biogenesis in skeletal muscle in response to chronic energy deprivation. Proceedings of the National Academy of Sciences of the United
States of America, 99, 15983–15987.

S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section.

How to cite this article: Strong R, Miller RA, Bogue M, et al.
Rapamycin-mediated mouse lifespan extension: Late-life
dosage regimes with sex-specific effects. Aging Cell.
2020;19:e13269. https://doi.org/10.1111/acel.13269

